Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.
Ontology highlight
ABSTRACT: PURPOSE:18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart. METHODS:Seventeen patients with proven cardiac amyloidosis underwent 18F-florbetapir PET/CT imaging, 15 with AL and 2 with transthyretin amyloidosis (ATTR). Three patients had repeat scans. All patients had protocolized assessment at the UK National Amyloidosis Centre including imaging with 123I-serum amyloid P component (SAP). 18F-Florbetapir images were assessed for areas of increased tracer accumulation and time-uptake curves in terms of standardized uptake values (SUVmean) were produced. RESULTS:All 17 patients showed 18F-florbetapir u
SUBMITTER: Wagner T
PROVIDER: S-EPMC5953997 | biostudies-literature | 2018 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA